Separately, StockNews.com cut shares of Syros Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, May 5th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Hold and a consensus target price of $13.83.
Shares of NASDAQ SYRS opened at $0.77 on Monday. The company has a 50-day moving average of $1.04 and a 200 day moving average of $2.27. Syros Pharmaceuticals has a 12-month low of $0.76 and a 12-month high of $7.03. The company has a current ratio of 4.33, a quick ratio of 4.33 and a debt-to-equity ratio of 0.47. The stock has a market cap of $47.78 million, a PE ratio of -0.56 and a beta of 2.14.
Several hedge funds have recently modified their holdings of SYRS. Morgan Stanley lifted its holdings in shares of Syros Pharmaceuticals by 7.8% in the 2nd quarter. Morgan Stanley now owns 403,339 shares of the company’s stock worth $2,198,000 after acquiring an additional 29,208 shares during the last quarter. Invesco Ltd. lifted its holdings in Syros Pharmaceuticals by 62.9% during the 2nd quarter. Invesco Ltd. now owns 18,214 shares of the company’s stock worth $99,000 after buying an additional 7,036 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Syros Pharmaceuticals during the 3rd quarter worth approximately $139,000. Deutsche Bank AG lifted its holdings in Syros Pharmaceuticals by 65.9% during the 3rd quarter. Deutsche Bank AG now owns 59,973 shares of the company’s stock worth $268,000 after buying an additional 23,815 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its holdings in Syros Pharmaceuticals by 233.0% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 78,535 shares of the company’s stock worth $351,000 after buying an additional 54,950 shares in the last quarter. Hedge funds and other institutional investors own 77.18% of the company’s stock.
About Syros Pharmaceuticals (Get Rating)
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
- Get a free copy of the StockNews.com research report on Syros Pharmaceuticals (SYRS)
- Etsy Buy!: Why Etsy Stock is Making a Crafty Comeback
- FIGS, Inc Moves Lower On Analysts’ Downgrades
- MarketBeat Podcast: Trading Volatile Markets While Preserving Capital
- Option Care Health Stock is Making a Healthy Pullback
- Warby Parker Stock Is A High-Probability Candidate For A Short-Squeeze
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.